Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome

Gastroenterology Clinics of North America

Volumn 39, Issue 3, 2010, Pages 481-493

  Camilleri, Michael ^a   Tack, Jan F ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clinical trials; Opioids; Pharmacodynamics; Pharmacology; Serotonergics

Indexed keywords

ACOTIAMIDE; ALEMCINAL; AMOXICILLIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CISAPRIDE; CLARITHROMYCIN; COLESTYRAMINE; DICYCLOVERINE; DIPHENOXYLATE; DOMPERIDONE; FEDOTOZINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITOPRIDE; LOPERAMIDE; MACROGOL; MAGNESIUM SALT; MEBEVERINE; MOSAPRIDE CITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OTILONIUM BROMIDE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 4 ANTAGONIST; TANDOSPIRONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CAUSAL ATTRIBUTION; CLINICAL TRIAL; DIET THERAPY; DIETARY INTAKE; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FIBER; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; IRRITABLE COLON; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PSYCHIATRIC TREATMENT; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ANALGESICS; ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; DRUGS, INVESTIGATIONAL; DYSPEPSIA; HISTAMINE H2 ANTAGONISTS; HUMANS; IRRITABLE BOWEL SYNDROME; LAXATIVES; PROTON PUMP INHIBITORS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957923650     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.08.005     Document Type: Review

References (80)

1. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580.
2. Cremonini F., Talley N.J. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005, 34:189-204.
3. Tack J., Bisschops R., Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004, 127:1239-1255.
4. Bredenoord A.J., Chial H.J., Camilleri M., et al. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003, 1:264-272.
5. Castillo E.J., Camilleri M., Locke G.R., et al. A community based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004, 2:985-996.
6. Van Oudenhove L., Vandenberghe J., Geeraerts B., et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation?. Gut 2008, 57(12):1666-1673.
7. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
8. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005, 17:311-316.
9. Sadik R., Stotzer P.O., Simrén M., et al. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 2008, 20:197-205.
10. Manabe N., Wong B.S., Camilleri M., et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010, 22(3):293.
11. Dunlop S.P., Coleman N.S., Blackshaw E., et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349-357.
12. Bearcroft C.P., Perrett D., Farthing M.J. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998, 42:42-46.
13. Houghton L.A., Atkinson W., Whitaker R.P., et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:663-670.
14. Roka R., Rosztoczy A., Leveque M., et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007, 5:550-555.
15. Borman R. Serotonergic modulation and irritable bowel syndrome. Expert Opin Emerg Drugs 2001, 6:57-68.
16. Spiller R.C. Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662-1671.
17. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
18. Spiller R.C. Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004, 2:445-455.
19. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693-702.
20. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
21. Aerssens J., Camilleri M., Talloen W., et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008, 6:194-205.
22. Tack J., Talley N.J., Camilleri M., et al. Functional gastroduodenal disorders. Gastroenterology 2006, 130(5):1466-1479.
23. Tack J., Talley N.J. Gastroduodenal disorders. Am J Gastroenterol 2010, 105(4):757-763.
24. Lassen A., Pedersen F., Bytzer P., et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomized trial. Lancet 2000, 356:455.
25. Ford A.C., Qume M., Moayyedi P., et al. Helicobacter pylori " test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005, 128(7):1838-1844.
26. Delaney B., Ford A.C., Forman D., et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005, 4. CD001961.
27. Talley N.J., Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005, 100(10):2324-2337.
28. National Institute for Clinical Excellence Dyspepsia: managing dyspepsia in adults in primary care 2004, NICE, London.
29. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of helicobacter pylori infection: the maastricht iii consensus report. Gut 2007, 56(6):772-781.
30. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, 2. CD002096.
31. Ladabaum U., Chey W.D., Scheiman J.M., et al. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmacol Ther 2002, 16:1491-1501.
32. Spiegel B., Vakil N., Ofman J. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002, 122:1270.
33. Rabeneck L., Souchek J., Wristers K., et al. A double-blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. Am J Gastroenterol 2002, 97:3045.
34. Moayyedi P., Soo S., Deeks J., et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, 4. CD001960.
35. Moayyedi P., Delaney B.C., Vakil N., et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004, 127(5):1329-1337.
36. Hallerbäck B.I., Bommelaer G., Bredberg E., et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002, 16(5):959-967.
37. Vakil N., Laine L., Talley N.J., et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008, 103(8):1906-1919.
38. Holtmann G., Talley N.J., Liebregts T., et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006, 354:832-840.
39. Talley N.J., Tack J., Ptak T., et al. Itopride in functional dyspepsia: results of two phase iii multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008, 57(6):740-746.
40. Talley N.J., Verlinden M., Snape W., et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000, 14(12):1653-1661.
41. Hojo M., Miwa H., Yokoyama T., et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005, 40(11):1036-1042.
42. Mertz H., Fass R., Kodner A., et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998, 93(2):160-165.
43. Tack J., Broekaert D., Coulie B., et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003, 17(4):603-608.
44. van Kerkhoven L.A., Laheij R.J., Aparicio N., et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008, 6(7):746-752.
45. Soo S., Moayyedi P., Deeks J., et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005, 2. CD002301.
46. Karamanolis G., Tack J. Promotility medications-now and in the future. Dig Dis 2006, 24(3-4):297-307.
47. Kindt S., Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006, 55(12):1685-1691.
48. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008, 8(6):690-696.
49. Miwa H., Nagahara A., Tominaga K., et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009, 104(11):2779-2787.
50. Tack J., Van Den Elzen B., Tytgat G., et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009, 21(6):619-626. e23-4.
51. Tack J., Masclee A., Heading R.C., et al. A dose-ranging, placebo-controlled pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009, 21(3):272-280.
52. Matsueda K., Hongo M., Tack J., et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010, 22(6):618.
53. Read N.W., Abitbol J.L., Bardhan K.D., et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41(5):664-668.
54. Talley N.J., Choung R.S., Camilleri M., et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008, 27(11):1122-1131.
55. Camilleri M., McKinzie S., Busciglio I., et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008, 6:772-781.
56. Voderholzer W.A., Schatke W., Mühldorfer B.E., et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997, 92:95-98.
57. Francis C.Y., Whorwell P.J. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994, 344:39-40.
58. Miller V., Lea R., Agrawal A., et al. Bran and irritable bowel syndrome: the primary-care perspective. Dig Liver Dis 2006, 38:737-740.
59. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008, 337:a2313.
60. Odunsi-Shiyanbade S.T., Camilleri M., McKinzie S., et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010, 8:159-165.
61. Andresen V., Montori V.M., Keller J., et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545-555.
62. Manabe N., Cremonini F., Camilleri M., et al. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther 2009, 30:930-936.
63. Johanson J.F., Drossman D.A., Panas R., et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008, 27:685-696.
64. Johnston J.M., Kurtz C.B., Drossman D.A., et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009, 104:125-132.
65. Lembo A.J., Kurtz C.B., Macdougall J.E., et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010, 138:886-895.
66. Stimmel G.L., Gutierrez M.A. Counseling patients about sexual issues. Pharmacotherapy 2006, 26:1608-1615.
67. Williams L.J., Pasco J.A., Jacka F.N., et al. Depression and bone metabolism. A review. Psychother Psychosom 2009, 78:16-25.
68. Enck P., Zimmermann K., Menke G., et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008, 20:1103-1109.
69. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010, 59:325-332.
70. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006, 145:557-563.
71. Houghton L.A., Fell C., Whorwell P.J., et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007, 56:1218-1225.
72. Gorard D.A., Libby G.W., Farthing M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:159-166.
73. Tack J., Broekaert D., Corsetti M., et al. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther 2006, 23:265-274.
74. Chial H.J., Camilleri M., Ferber I., et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003, 1:211-218.
75. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009, 58:367-378.
76. Rahimi R., Nikfar S., Rezaie A., et al. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009, 15:1548-1553.
77. Vahedi H., Merat S., Rashidioon A., et al. Effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005, 22:381-385.
78. Vahedi H., Merat S., Momtahen S., et al. Clinical trial: effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008, 27:678-684.
79. Bergmann M., Heddergott A., Schlosser T. Die therapie des colon irritabile mit trimaprimin (Herphonal)-eine kontrollierte studie. Z Klin Med 1991, 46:1621-1628.
80. Saps M., Youssef N., Miranda A., et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009, 137:1261-1269.